[go: up one dir, main page]

PE20070360A1 - Composiciones de liposomas - Google Patents

Composiciones de liposomas

Info

Publication number
PE20070360A1
PE20070360A1 PE2006001052A PE2006001052A PE20070360A1 PE 20070360 A1 PE20070360 A1 PE 20070360A1 PE 2006001052 A PE2006001052 A PE 2006001052A PE 2006001052 A PE2006001052 A PE 2006001052A PE 20070360 A1 PE20070360 A1 PE 20070360A1
Authority
PE
Peru
Prior art keywords
liposomes
therapeutic agent
liposome compositions
composition
cations
Prior art date
Application number
PE2006001052A
Other languages
English (en)
Inventor
Saran Kumar
Wenlei Jiang
Jia-Ai Zhang
Jorg Ogorka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37715942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070360A1 publication Critical patent/PE20070360A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIPOSOMAS QUE COMPRENDE UNA MATRIZ DE CATIONES DIVALENTES TALES COMO IONES DE CAlCIO O CATIONES DE ZINC O MAGNESIO, LA CUAL CONTIENE UN AGENTE TERAPEUTICO DE FORMULA I, DONDE R1 ES HETEROCICLO DE 5 MIEMBROS, QUE CONTIENE COMO HETEROATOMOS DE N, O, S, Y EL CUAL ESTA SUSTITUIDO POR ALQUILO INFERIOR, FENILO, ENTRE OTROS. DICHO AGENTE TERAPEUTICO ES DE PREFERENCIA ACIDO ZOLEDRONICO. LA COMPOSICION DE LIPOSOMAS TIENE UN TAMANO DE PARTICULA PROMEDIO DE APROXIMADAMENTE 10-500 NANOMETROS Y COMPRENDE ADEMAS UN LIGANDO EFECTIVO PARA ENLAZARSE ESPECIFICAMENTE A UN ANTIGENO ESPECIFICO DEL TUMOR
PE2006001052A 2005-09-01 2006-08-29 Composiciones de liposomas PE20070360A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71327305P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
PE20070360A1 true PE20070360A1 (es) 2007-04-19

Family

ID=37715942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001052A PE20070360A1 (es) 2005-09-01 2006-08-29 Composiciones de liposomas

Country Status (14)

Country Link
US (1) US20080286352A1 (es)
EP (1) EP1924247A2 (es)
JP (1) JP2009507029A (es)
KR (1) KR20080038379A (es)
CN (1) CN101252912A (es)
AR (1) AR055621A1 (es)
AU (1) AU2006284642A1 (es)
BR (1) BRPI0616598A2 (es)
CA (1) CA2620400A1 (es)
GT (1) GT200600391A (es)
PE (1) PE20070360A1 (es)
RU (1) RU2008111967A (es)
TW (1) TW200744669A (es)
WO (1) WO2007028020A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
WO2010143193A1 (en) * 2009-06-11 2010-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
ITNA20100046A1 (it) * 2010-09-28 2012-03-29 Abbruzzese Saccardi Alberto Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico
IT1401882B1 (it) * 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
EP2823811A1 (en) 2013-07-09 2015-01-14 OTC GmbH Targeted active release system comprising solid lipid nano-particles
US9950065B2 (en) 2013-09-26 2018-04-24 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
KR20200018407A (ko) * 2017-04-28 2020-02-19 텍사스 칠드런스 하스피탈 표적화 나노입자
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
EP3954386A4 (en) 2019-04-11 2022-07-06 Xiamen Innovax Biotech Co., Ltd. PREPARATION OF A ZINC ZOLEDRONATE MICRO-NANOPARTICLE ADJUVANT AND ITS USE AS A VACCINE ADJUVANT
TWI763991B (zh) * 2019-05-02 2022-05-11 行政院原子能委員會核能研究所 新式眼用凝膠及其製備方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
HU225069B1 (en) * 1997-09-09 2006-06-28 Lyotropic Therapeutics Coated particles, methods of making and using
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US7090865B2 (en) * 2001-11-29 2006-08-15 National Jewish Medical And Research Center Composition and method for treating autoimmune hemolytic anemia
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体

Also Published As

Publication number Publication date
WO2007028020A3 (en) 2007-05-31
US20080286352A1 (en) 2008-11-20
WO2007028020A2 (en) 2007-03-08
JP2009507029A (ja) 2009-02-19
GT200600391A (es) 2007-04-02
AR055621A1 (es) 2007-08-29
AU2006284642A1 (en) 2007-03-08
TW200744669A (en) 2007-12-16
CN101252912A (zh) 2008-08-27
BRPI0616598A2 (pt) 2011-06-28
EP1924247A2 (en) 2008-05-28
CA2620400A1 (en) 2007-03-08
RU2008111967A (ru) 2009-10-10
KR20080038379A (ko) 2008-05-06

Similar Documents

Publication Publication Date Title
PE20070360A1 (es) Composiciones de liposomas
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
PE20090113A1 (es) Compuestos triciclicos como moduladores del receptor de glucocorticoides, composiciones y procedimientos
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
EA200802428A1 (ru) Комбинации агентов для биологической борьбы и нематоцидов, входящих в покрытие семян
HN2008001374A (es) Compuestos de cinamida policiclicos
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
CR10642A (es) Composicion pesticida
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
HN2010000674A (es) Composicion y metodos de uso para anticuerpos contra la esclerostina
EA201001639A1 (ru) Композиции и способы их получения и применения
CL2011000774A1 (es) Formulacion farmaceutica que comprende el compuesto 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona en dispersion solida con un polimero de matriz; correspondiente a copovidona, util en el tratamiento del cancer.
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA201171284A1 (ru) Новая технология изготовления напроксена
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
HN2008000582A (es) Composiciones de suplementos de hierro de tolerancia mejorada
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
BR112013017267A8 (pt) formulação de lipossomas, suspensão e composição farmacêutica
EA201071369A1 (ru) Композиции для лечения выпадения волос
UY30675A1 (es) Metodos para el tratamiento de la depresion

Legal Events

Date Code Title Description
FD Application declared void or lapsed